KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

N Colombo, A Gadducci, J Sehouli, E Rulli, J Mäenpää, C Sessa, A Montes, N B Ottevanger, R Berger, I Vergote, M D'Incalci, C Churruca Galaz, R Chekerov, G B Nyvang, S Riniker, R Herbertson, R Fossati, M P Barretina-Ginesta, M Deryal, M R Mirza, E Biagioli, M Iglesias, G Funari, M Romeo, G Tasca, B Pardo, G Tognon, M J Rubio-Pérez, A DeCensi, U De Giorgi, P Zola, P Benedetti Panici, M Aglietta, V Arcangeli, C Zamagni, A Bologna, A Westermann, V Heinzelmann-Schwarz, I Tsibulak, P Wimberger, A Poveda, INOVATYON study group

Br J Cancer 128(8) 1503-1513

PMID36759720
PMCIDPMC10070417
DOI10.1038/s41416-022-02108-7
发表日期2023-02-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

BACKGROUND: This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). METHODS: Patients with OC (up to two previous platinum-based lines), with a TFIp of 6-12 months, were randomised to receive carboplatin/PLD (CP) or TP followed by platinum therapy at relapse. The primary endpoint was OS (HR: 0.75). RESULTS: The study enrolled 617 patients. The median TFIp was 8.3 months and 30.3% of patients had received two previous platinum lines. 74% and 73.9% of patients, respectively, received a subsequent therapy (ST) in the CP and TP arm; in the latter TP arm 87.2% of ST was platinum-based, as per protocol. The median OS was 21.4 for CP and 21.9 months for TP (HR 1.13; 95% CI: 0.94-1.35; p = 0.197). Grade 3-5 adverse reactions occurred in 37.1% of patients in the CP arm and 69.7% of patients in the TP arm, and the most frequent were neutropenia (22.8% CP, 39.5% TP), gastrointestinal (7.1% CP, 17.4% TP), hepatic (0.7% CP, 19.1% TP). CONCLUSIONS: This study did not meet the primary endpoint. CP combination remains the standard for patients with recurrent OC and a 6-12 months TFIp; TP is an effective treatment in patients suffering from persistent platinum toxicities. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, number NCT01379989.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。